<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;A10B&quot;,&quot;href&quot;:&quot;atc/A10B.md&quot;},{&quot;label&quot;:&quot;pioglitazone&quot;}]"></div>

# pioglitazone

- **generic name:** pioglitazone
- **ATC codes:** `A10BD05`, `A10BD06`, `A10BD09`, `A10BD12`, `A10BG03`
- **DrugBank:** [DB01132](https://go.drugbank.com/drugs/DB01132) · **PubChem:** [CID 4829](https://pubchem.ncbi.nlm.nih.gov/compound/4829)
- **molar mass:** 356.439 g/mol (C19H20N2O3S) — DrugBank
- **groups:** approved, investigational

## About

Pioglitazone is an anti-diabetic medicine used to lower blood sugar in type 2 diabetes. It remains authorised in the European Union, though several products there have been withdrawn, and it is also available in fixed-dose combinations with other oral diabetes drugs.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q417765](https://www.wikidata.org/wiki/Q417765) and the WHO ATC classification and the EMA medicines list; not checked by a person.</small>

## Molecules and molar masses

> The molar mass each model uses to convert mass to molar concentration and to form a metabolite molecule for molecule. Looked up, never estimated: DrugBank for the drug, the paper's own value or the PubChem entry matched to the paper's name for a metabolite.

| molecule | role | molar mass (g/mol) | formula | source | PubChem | records |
|---|---|---|---|---|---|---|
| pioglitazone | parent | 356.439 | C19H20N2O3S | DrugBank | [4829](https://pubchem.ncbi.nlm.nih.gov/compound/4829) | Kadam_2013 |
| carboxylic acid metabolite | metabolite | — (mass units only) | — | — | — | — |
| enzalutamide | metabolite | 464.437 | C21H16F4N4O2S | PubChem | [15951529](https://pubchem.ncbi.nlm.nih.gov/compound/15951529) | Gibbons_2015 |
| N-desmethyl enzalutamide | metabolite | 450.41 | C20H14F4N4O2S | PubChem | [70678916](https://pubchem.ncbi.nlm.nih.gov/compound/70678916) | Gibbons_2015 |

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-05 02:52 | 7:27 | 0/1/1 | 0/0/0 | 0/0/5 | 130,458/18,170 | ollama / qwen3.8:27b-mtp-q8_0 | 6 | 2/4 | 6/0 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--orange">needs review</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.778). The first reading is what the record holds.">cross-check: disputed</span><br><sub>blocking: disposition incomplete — only volume extracted — the engineer needs clearance/e…</sub><br><sub>route_to: `human_review`</sub> | [Kadam_2013_reference](drugs/drug_pioglitazone/Pioglitazone_Kadam2013_reference.md) | — | 2-compartment (no model) | 3 | Kadam R et al., Effect of Cytochrome P450 2C8*3 on the…, Biological & pharmaceutical… (2013) | [10.1248/bpb.b12-00657](https://doi.org/10.1248/bpb.b12-00657) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.6). The first reading is what the record holds.">cross-check: disputed</span><br><sub>blocking: C8 unreachable/orphan compartment or unlinked metabolite</sub><br><sub>route_to: `human_review`</sub> | [Gibbons_2015_reference](drugs/drug_pioglitazone/Pioglitazone_Gibbons2015_reference.md) | — | general linear (no model) | 5 | Gibbons JA et al., Pharmacokinetic Drug Interaction Studie…, Clinical pharmacokinetics (2015) | [10.1007/s40262-015-0283-1](https://doi.org/10.1007/s40262-015-0283-1) |

## Pharmacogenomics (PGx)

| status | gene | affects | mechanism | detail | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.25). The first reading is what the record holds.">cross-check: partial</span> | **CYP2C8** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | metabolism | [Kadam_2013](drugs/drug_pioglitazone/pgx_Kadam_2013_CYP2C8_Q100.md) | Kadam R et al., Effect of Cytochrome P450 2C8*3 on the…, Biological & pharmaceutical… (2013) | [10.1248/bpb.b12-00657](https://doi.org/10.1248/bpb.b12-00657) |
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> <span class="pk-badge pk-badge--green" title="re-read by gpt-oss:120b (confirmed, agreement 1.0). The first reading is what the record holds.">cross-checked ✓</span> | **ADORA1** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | target | [Kawaguchi-Suzuki_2018](drugs/drug_pioglitazone/pgx_Kawaguchi_Suzuki_2018_ADORA1_Q100.md) | Kawaguchi-Suzuki M et al., A Genetic Score Associates With Pioglit…, Frontiers in pharmacology (2018) | [10.3389/fphar.2018.00752](https://doi.org/10.3389/fphar.2018.00752) |
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> <span class="pk-badge pk-badge--green" title="re-read by gpt-oss:120b (confirmed, agreement 1.0). The first reading is what the record holds.">cross-checked ✓</span> | **CYP2C8** | `Q27` · CL/F | metabolism | [Kawaguchi-Suzuki_2018](drugs/drug_pioglitazone/pgx_Kawaguchi_Suzuki_2018_CYP2C8_Q27.md) | Kawaguchi-Suzuki M et al., A Genetic Score Associates With Pioglit…, Frontiers in pharmacology (2018) | [10.3389/fphar.2018.00752](https://doi.org/10.3389/fphar.2018.00752) |
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.5). The first reading is what the record holds.">cross-check: disputed</span> | **LPL** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | unknown | [Kawaguchi-Suzuki_2018](drugs/drug_pioglitazone/pgx_Kawaguchi_Suzuki_2018_LPL_Q100.md) | Kawaguchi-Suzuki M et al., A Genetic Score Associates With Pioglit…, Frontiers in pharmacology (2018) | [10.3389/fphar.2018.00752](https://doi.org/10.3389/fphar.2018.00752) |
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.25). The first reading is what the record holds.">cross-check: partial</span> | **PPARG** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | target | [Kawaguchi-Suzuki_2018](drugs/drug_pioglitazone/pgx_Kawaguchi_Suzuki_2018_PPARG_Q100.md) | Kawaguchi-Suzuki M et al., A Genetic Score Associates With Pioglit…, Frontiers in pharmacology (2018) | [10.3389/fphar.2018.00752](https://doi.org/10.3389/fphar.2018.00752) |

<details class="pk-legend"><summary>What the PGx badges mean — evidence, and whether a model runs</summary><table><tbody><tr><td><span class="pk-badge pk-badge--green">quantitative</span></td><td>the paper gives the effect of each phenotype (or genotype) on a named model parameter — a θ per category.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">qualitative</span></td><td>the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">guideline estimate</span></td><td>the effect comes from a CPIC / DPWG dosing guideline, not from this paper's numbers.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">safety allele</span></td><td>a risk allele for an adverse reaction (an HLA type, G6PD deficiency …): it changes no PK/PD parameter.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>the extraction is incomplete or inconsistent.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted.</td></tr><tr><td><span class="pk-badge pk-badge--green">▶ simulatable</span></td><td>the paper's popPK model runs per phenotype in the browser (Simulation tab); its PGx Modelica model is under Models.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">model only</span></td><td>a PGx Modelica model exists but has no in-browser simulator.</td></tr></tbody></table></details>

<details class="legend">
<summary>What the PGx columns mean</summary>
<table><thead><tr><th>column</th><th>what it holds</th></tr></thead><tbody><tr><td><code>gene</code></td><td>the gene whose variants the record is about. One record per gene, so a paper reporting several genes appears on several rows.</td></tr><tr><td><code>affects</code></td><td>the PK or PD parameter the genotype SHIFTS, as an ontology Q-code plus its name — Q22 = clearance, Q27 = CL/F (apparent clearance), Q32 = Cmax, Q88 = AUC, Q40 = Fab, Q321 = EC50, Q322 = IC50, Q305 = kfm. The record's per-phenotype theta is a multiplier ON that parameter: a poor-metaboliser theta shifts this value, it does not supply one. Two values are NOT parameters — Q100 (NIL) is an association or risk finding with no parameter target, and `safety` is an adverse-reaction risk such as an HLA allele. A PA… id instead of a Q-code marks a record derived from a ClinPGx/PharmGKB guideline lookup rather than read out of the paper.</td></tr><tr><td><code>mechanism</code></td><td>how the gene acts: metabolism, transport, target, formation, safety_allele, or unknown.</td></tr><tr><td><code>detail</code></td><td>the paper stem, linking to the full record page.</td></tr><tr><th colspan="2" style="text-align:left;padding-top:10px">placeholders</th></tr><tr><td><code>not captured</code></td><td>the field is absent from the KB artifact — nothing was recorded. This is NOT the same as zero or empty: the value is unknown, not measured to be nothing.</td></tr><tr><td><code>—</code></td><td>deliberately not shown: the column does not apply to this row.</td></tr><tr><td><code>not verified</code></td><td>the record is not in an accepted state (see the badge and the note above the table); the numbers are shown as extracted, not endorsed.</td></tr></tbody></table>
</details>

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=pioglitazone) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| absorption | small intestine | <sub>named in DrugBank's ADME text</sub> | prose |
| distribution | blood | `ALB` substrate | DrugBank actor |
| metabolism | brain | `MAOB` inhibitor | DrugBank actor |
| metabolism | liver | `CYP2C8` inhibitor/metabolism/substrate, `CYP3A4` inducer/substrate, `SLCO1B1` inhibitor, `SLCO1B3` inhibitor | DrugBank actor |
| metabolism | lung | `CYP1A1` substrate | DrugBank actor |
| metabolism | platelet | `MAOB` inhibitor | DrugBank actor |
| metabolism | small intestine | `CYP1A1` substrate, `CYP3A4` inducer/substrate | DrugBank actor |
| excretion | bile duct | <sub>named in DrugBank's ADME text</sub> | prose |
| excretion | kidney | <sub>named in DrugBank's ADME text</sub> | prose |
| excretion | small intestine | <sub>named in DrugBank's ADME text</sub> | prose |

<sub>Actors without a tissue in the table: ADORA1 (target), LPL (unknown), PPARG (target).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 231 matched, 62 returned
- **screened:** 6  ·  **relevant:** 2
- **records:** 2  ·  extracted 0  ·  needs_review 1  ·  rejected 1  ·  stale 0
- **scholar-agent fallback query used:** not captured

## Full text wanted

_20 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Clark_2012.pdf` | Clark MH et al., Pharmacokinetics of pioglitazone in lea…, Journal of veterinary pharm… (2012) | popPK | 10 | [10.1111/j.1365-2885.2011.01341.x](https://doi.org/10.1111/j.1365-2885.2011.01341.x) | [22612529](https://pubmed.ncbi.nlm.nih.gov/22612529) | The study reports quantitative pharmacokinetic parameters (bioavailability, half-life, Tmax, Cmax, AUC) for pioglitazone in cats, with specific values provided in the abstract. |
| `Sherwin_2011.pdf` | Sherwin CM et al., Optimal study design for pioglitazone i…, Journal of pharmacokinetics… (2011) | popPK | 8 | [10.1007/s10928-011-9202-8](https://doi.org/10.1007/s10928-011-9202-8) | [21667139](https://pubmed.ncbi.nlm.nih.gov/21667139) | The paper describes a population PK model for pioglitazone in pediatric patients, but the specific numeric parameter values (CL, V, etc.) are not explicitly listed in the provided text, only referenced as being comparable to literature or derived from simulations. |
| `El-Shoukrofy_2025.pdf` | El-Shoukrofy MS et al., Novel thiazolones for the simultaneous…, European journal of medicin… (2025) | pd | 5 | [10.1016/j.ejmech.2025.117415](https://doi.org/10.1016/j.ejmech.2025.117415) | [40022874](https://www.ncbi.nlm.nih.gov/pubmed/40022874) | metadata signals extractable PD data (IC50) |
| `Goto_2017.pdf` | Goto A et al., Influence of the pharmacokinetic profil…, Biopharmaceutics & drug dis… (2017) | pd | 5 | [10.1002/bdd.2076](https://doi.org/10.1002/bdd.2076) | [28294376](https://www.ncbi.nlm.nih.gov/pubmed/28294376) | metadata signals extractable PD data (PK/PD) |
| `Matthews_2009.pdf` | Matthews L et al., Thiazolidinediones are partial agonists…, Endocrinology (2009) | pd | 4 | [10.1210/en.2008-0196](https://doi.org/10.1210/en.2008-0196) | [18801908](https://www.ncbi.nlm.nih.gov/pubmed/18801908) | metadata signals extractable PD data (EC50) |
| `Sears_2007.pdf` | Sears DD et al., Selective modulation of promoter recrui…, Biochemical and biophysical… (2007) | pd | 4 | [10.1016/j.bbrc.2007.10.057](https://doi.org/10.1016/j.bbrc.2007.10.057) | [17963725](https://www.ncbi.nlm.nih.gov/pubmed/17963725) | metadata signals extractable PD data (EC50) |
| `Aquilante_2013.pdf` | Aquilante CL et al., Impact of the CYP2C8 *3 polymorphism on…, British journal of clinical… (2013) | pgx | 8 | [10.1111/j.1365-2125.2012.04343.x](https://doi.org/10.1111/j.1365-2125.2012.04343.x) | [22625877](https://www.ncbi.nlm.nih.gov/pubmed/22625877) | metadata signals extractable PGX data (CYP2C8, PK/PD-context) |
| `Dawed_2016.pdf` | Dawed AY et al., CYP2C8 and SLCO1B1 Variants and Therape…, Diabetes care (2016) | pgx | 8 | [10.2337/dc15-2464](https://doi.org/10.2337/dc15-2464) | [27271184](https://www.ncbi.nlm.nih.gov/pubmed/27271184) | metadata signals extractable PGX data (CYP2C8, PK/PD-context) |
| `Kalliokoski_2010.pdf` | Kalliokoski A et al., SLCO1B1 polymorphism and oral antidiabe…, Basic & clinical pharmacolo… (2010) | pgx | 8 | [10.1111/j.1742-7843.2010.00581.x](https://doi.org/10.1111/j.1742-7843.2010.00581.x) | [20406215](https://www.ncbi.nlm.nih.gov/pubmed/20406215) | metadata signals extractable PGX data (SLCO1B1, PK/PD-context) |
| `Tornio_2008.pdf` | Tornio A et al., Trimethoprim and the CYP2C8*3 allele ha…, Drug metabolism and disposi… (2008) | pgx | 8 | [10.1124/dmd.107.018010](https://doi.org/10.1124/dmd.107.018010) | [17913794](https://www.ncbi.nlm.nih.gov/pubmed/17913794) | metadata signals extractable PGX data (CYP2C8*3, PK/PD-context) |
| `Albassam_2019.pdf` | Albassam AA et al., Effect of pterostilbene on in vitro dru…, Saudi pharmaceutical journa… (2019) | pgx | 7 | [10.1016/j.jsps.2019.01.001](https://doi.org/10.1016/j.jsps.2019.01.001) | [30976185](https://www.ncbi.nlm.nih.gov/pubmed/30976185) | metadata signals extractable PGX data (CYP2C8, PK/PD-context) |
| `Choi_2016.pdf` | Choi JS et al., Effects of pioglitazone on the pharmaco…, European journal of drug me… (2016) | pgx | 7 | [10.1007/s13318-014-0249-y](https://doi.org/10.1007/s13318-014-0249-y) | [25549928](https://www.ncbi.nlm.nih.gov/pubmed/25549928) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Cui_2008.pdf` | Cui X et al., Application and interpretation of hPXR…, Biochemical pharmacology (2008) | pgx | 7 | [10.1016/j.bcp.2008.06.016](https://doi.org/10.1016/j.bcp.2008.06.016) | [18647599](https://www.ncbi.nlm.nih.gov/pubmed/18647599) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Dey_2020.pdf` | Dey S et al., Simultaneous Pharmacokinetics Estimatio…, Journal of chromatographic… (2020) | pgx | 7 | [10.1093/chromsci/bmz116](https://doi.org/10.1093/chromsci/bmz116) | [31836899](https://www.ncbi.nlm.nih.gov/pubmed/31836899) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |
| `Jaakkola_2005.pdf` | Jaakkola T et al., Effects of gemfibrozil, itraconazole, a…, Clinical pharmacology and t… (2005) | pgx | 7 | [10.1016/j.clpt.2004.12.266](https://doi.org/10.1016/j.clpt.2004.12.266) | [15900286](https://www.ncbi.nlm.nih.gov/pubmed/15900286) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Jaakkola_2006.pdf` | Jaakkola T et al., Pioglitazone is metabolised by CYP2C8 a…, Basic & clinical pharmacolo… (2006) | pgx | 7 | [10.1111/j.1742-7843.2006.pto_437.x](https://doi.org/10.1111/j.1742-7843.2006.pto_437.x) | [16867170](https://www.ncbi.nlm.nih.gov/pubmed/16867170) | metadata signals extractable PGX data (CYP2C8, PK/PD-context) |
| `Mamindla_2017.pdf` | Mamindla S et al., Effect of Cinnamomum cassia on the Phar…, Current clinical pharmacolo… (2017) | pgx | 7 | [10.2174/1574884712666170207152020](https://doi.org/10.2174/1574884712666170207152020) | [28176623](https://www.ncbi.nlm.nih.gov/pubmed/28176623) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Pradeepkumar_2022.pdf` | Pradeepkumar B et al., Influence of trazodone on the pharmacod…, Indian journal of pharmacol… (2022) | pgx | 7 | [10.4103/ijp.ijp_311_20](https://doi.org/10.4103/ijp.ijp_311_20) | [35848690](https://www.ncbi.nlm.nih.gov/pubmed/35848690) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Takanohashi_2007.pdf` | Takanohashi T et al., Prediction of the metabolic interaction…, Drug metabolism and pharmac… (2007) | pgx | 7 | [10.2133/dmpk.22.409](https://doi.org/10.2133/dmpk.22.409) | [18159128](https://www.ncbi.nlm.nih.gov/pubmed/18159128) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |
| `Yates_2012.pdf` | Yates P et al., Statistical methods for analysis of tim…, Drug metabolism and disposi… (2012) | pgx | 7 | [10.1124/dmd.112.047233](https://doi.org/10.1124/dmd.112.047233) | [22942318](https://www.ncbi.nlm.nih.gov/pubmed/22942318) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |

<sub>queue written 2026-10-05T02:46:10.826656+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | Abushammala_2015 | irrelevant | 1 | 0 | The study reports pharmacokinetic parameters for carbamazepine (the subject drug), while pioglitazone is only a co-administered agent to test for drug-drug interactions, and no PK parameters for pioglitazone itself are provided. |
| PGx | Abushammala_2015 | not_relevant | 0 | 0 | The study investigates a drug-drug interaction in rabbits and does not report any pharmacogenomic effects or genetic variants. |
| popPK | Aftab_2019 | irrelevant | 0 | 0 | The study is a clinical efficacy trial for bipolar depression and does not report any pharmacokinetic parameters for pioglitazone. |
| PGx | Albassam_2019 | not_relevant | 0 | 0 | The paper studies the effect of pterostilbene on enzyme activity and does not involve pioglitazone or any genetic variants. |
| popPK | Almeida_2011 | irrelevant | 2 | 0 | The study is a bioequivalence assessment using non-compartmental analysis (AUC, Cmax) and does not report compartmental PK parameters (CL, V, ka) or population PK model values in the provided text. |
| PGx | Choi_2016 | not_relevant | 0 | 0 | The study investigates drug-drug interactions (pioglitazone affecting nifedipine PK) in rats, not the effect of a gene variant on pioglitazone's PK/PD. |
| PGx | Cui_2008 | not_relevant | 0 | 0 | The paper validates a PXR assay for CYP3A4 induction and mentions pioglitazone as a false positive in the assay, but it does not report any pharmacogenomic effect (gene variant/genotype) on pioglitazone's PK or PD parameters. |
| PGx | Dawed_2016 | not_relevant | 0 | 0 | The study explicitly states that neither CYP2C8 nor SLCO1B1 variants had a significant impact on pioglitazone response. |
| PGx | Dey_2020 | not_relevant | 0 | 0 | The paper describes a drug-drug interaction (pioglitazone inhibiting nateglinide metabolism) and a method development study, but does not report any pharmacogenomic effects (gene variants) on pioglitazone PK/PD. |
| popPK | El-Shoukrofy_2025 | irrelevant | 0 | 0 | no_text gate: only 136 chars of text extracted (&lt; 400) |
| PD | El-Shoukrofy_2025 | not_relevant | 0 | 0 | The paper focuses on novel thiazolones and does not report pharmacodynamic or exposure-response data for pioglitazone. |
| PGx | Gibbons_2015 | not_relevant | 0 | 0 | The paper reports drug-drug interactions (enzalutamide with CYP substrates) but does not investigate the effect of gene variants or genotypes on pharmacokinetic or pharmacodynamic parameters. |
| popPK | Goto_2017 | irrelevant | 0 | 0 | no_text gate: only 133 chars of text extracted (&lt; 400) |
| PD | Goto_2017 | not_relevant | 0 | 0 | The provided text is only the title of the paper and does not contain the full text, data, or numeric PD parameters required to assess the exposure-response relationship. |
| popPK | Gupta_2023 | irrelevant | 0 | 0 | The study focuses on the design and antidiabetic efficacy of novel thiazolidine derivatives, using pioglitazone only as a reference drug for comparison in in vivo and in vitro assays, with no pharmacokinetic parameters reported. |
| popPK | Hamrén_2012 | irrelevant | 0 | 0 | The study focuses on the pharmacokinetics of tesaglitazar, with pioglitazone serving only as a comparator arm without reported PK parameters. |
| PD | Hamrén_2012 | not_relevant | 0 | 0 | The paper focuses on the pharmacokinetic-pharmacodynamic modeling of tesaglitazar, not pioglitazone; pioglitazone is only mentioned as a comparator arm without specific PD parameter analysis. |
| PGx | He_2012 | not_relevant | 0 | 0 | The paper focuses on the pharmacokinetics and pharmacodynamics of vildagliptin, not pioglitazone, and does not report any pharmacogenomic effects on pioglitazone. |
| popPK | Hwang_2020 | irrelevant | 2 | 0 | The study reports only relative geometric mean ratios (GMRs) for interaction assessment, not absolute quantitative disposition parameters (CL, V, t1/2) for pioglitazone. |
| PD | Hwang_2020 | not_relevant | 2 | 1 | The study reports qualitative changes in glucose levels and PK parameters (Cmax, AUC) but does not provide numeric PD parameters (e.g., Emax, EC50) or a quantitative concentration-effect model for pioglitazone. |
| PGx | Jaakkola_2005 | not_relevant | 0 | 0 | The study investigates drug-drug interactions (gemfibrozil/itraconazole) rather than the effect of a specific gene variant or genotype on pioglitazone pharmacokinetics. |
| PGx | Jaakkola_2006 | not_relevant | 0 | 0 | The study investigates in vitro metabolism and drug-drug interactions with CYP inhibitors, not the effect of genetic variants (pharmacogenomics) on pharmacokinetic or pharmacodynamic parameters. |
| PGx | Kalliokoski_2010 | not_relevant | 0 | 0 | The paper explicitly states that SLCO1B1 genotype has no effect on the pharmacokinetics of pioglitazone. |
| popPK | Kasahara_2016 | irrelevant | 1 | 0 | Pioglitazone is a co-administered comparator drug in a study focused on tofogliflozin, and no specific quantitative PK parameters for pioglitazone are reported in the evidence. |
| PD | Kasahara_2016 | not_relevant | 0 | 0 | The study evaluates drug-drug interactions on tofogliflozin's PK/PD and co-administered drugs' PK, but does not report a concentration- or dose-response relationship for pioglitazone itself. |
| PGx | Kawaguchi-Suzuki_2018 | not_relevant | 5 | 5 | The paper reports pharmacodynamic associations (clinical response/histology) but does not report changes in pharmacokinetic parameters (e.g., AUC, Cmax) or fitted effect sizes for PK. |
| popPK | Kumar_2006 | irrelevant | 0 | 0 | The study investigates the pharmacokinetics of centchroman in rats, with pioglitazone serving only as a co-administered drug for interaction testing. |
| PD | Kumar_2006 | not_relevant | 0 | 0 | The paper investigates drug-drug interactions on the pharmacokinetics of centchroman, not the pharmacodynamics of pioglitazone; pioglitazone is only a co-administered agent in a PK interaction study. |
| PGx | Loer_2022 | not_relevant | 0 | 0 | The paper focuses on the pharmacokinetics of clopidogrel; pioglitazone is only mentioned as a co-administered drug in a drug-drug interaction (DDI) simulation, not as the subject of a pharmacogenomic study. |
| PGx | Ly_2021 | not_relevant | 0 | 0 | The paper investigates CYP3A induction by pioglitazone in a transgenic mouse model, not the effect of a human gene variant on pioglitazone's PK/PD. |
| PGx | Mamindla_2017 | not_relevant | 0 | 0 | The study investigates a drug-herb interaction (cinnamon) rather than a pharmacogenomic effect (gene variant/genotype). |
| popPK | Matthews_2009 | irrelevant | 0 | 0 | no_text gate: only 71 chars of text extracted (&lt; 400) |
| PD | Matthews_2009 | not_relevant | 0 | 0 | The provided text is a title/abstract snippet regarding the mechanism of action (glucocorticoid receptor partial agonism) and does not contain any PK/PD data, exposure-response analysis, or numeric PD parameters for pioglitazone. |
| PGx | Nowak_2002 | not_relevant | 0 | 0 | The study evaluates the effect of pioglitazone on CYP3A4 activity in a general population without stratifying by genotype or reporting pharmacogenomic effects. |
| PGx | Ogilvie_2006 | not_relevant | 0 | 0 | The paper investigates the mechanism of gemfibrozil's inhibition of CYP2C8 and its implications for drug-drug interactions, but it does not report any pharmacogenomic effects (gene variants) on the PK or PD of pioglitazone. |
| popPK | Ormseth_2013 | irrelevant | 0 | 0 | The study is a clinical trial evaluating the efficacy of pioglitazone on rheumatoid arthritis disease activity and insulin resistance, and does not report any pharmacokinetic parameters (e.g., clearance, volume, half-life). |
| popPK | Ormseth_2014 | irrelevant | 0 | 0 | The study is a clinical trial assessing vascular function and blood pressure outcomes, not a pharmacokinetic study, and reports no PK parameters. |
| PGx | Pradeepkumar_2022 | not_relevant | 0 | 0 | The study investigates a drug-drug interaction (trazodone) rather than a pharmacogenomic effect (gene variant/genotype). |
| popPK | Sears_2007 | irrelevant | 0 | 0 | no_text gate: only 86 chars of text extracted (&lt; 400) |
| PD | Sears_2007 | not_relevant | 0 | 0 | The paper focuses on the molecular mechanism of PPARgamma promoter recruitment and transcriptional activity, not on pharmacokinetic or pharmacodynamic exposure-response modeling for pioglitazone. |
| popPK | Sherwin_2011 | relevant | 8 | 2 | The paper describes a population PK model for pioglitazone in pediatric patients, but the specific numeric parameter values (CL, V, etc.) are not explicitly listed in the provided text, only referenced as being comparable to literature or derived from simulations. |
| PGx | Singh_2019 | not_relevant | 0 | 0 | The paper evaluates the PXR activation potential of pioglitazone to predict drug-drug interactions, but does not report pharmacogenomic effects of gene variants on PK or PD parameters. |
| PGx | Spence_2020 | not_relevant | 0 | 0 | The paper discusses the clinical efficacy of pioglitazone in stroke prevention but does not report any pharmacogenomic effects on its pharmacokinetic or pharmacodynamic parameters. |
| PGx | Sun_2017 | not_relevant | 0 | 0 | The paper focuses on in-vitro CYP3A4 induction modeling and perpetrator concentration corrections, not on pharmacogenomic effects of gene variants on pioglitazone PK/PD. |
| PGx | Takanohashi_2007 | not_relevant | 0 | 0 | The paper investigates drug-drug interactions (inhibition of nateglinide metabolism by pioglitazone) in vitro, not pharmacogenomic effects of genetic variants on pioglitazone PK/PD. |
| popPK | Tran_2026 | irrelevant | 0 | 0 | The study is a model-based meta-analysis of pioglitazone's efficacy on histological and liver enzyme outcomes in MASH, not a pharmacokinetic study reporting disposition parameters. |
| PGx | Türk_2020 | not_relevant | 0 | 0 | The paper focuses on a PBPK model for trimethoprim and its interactions; pioglitazone is only mentioned as a co-administered drug for validation, and no specific pharmacogenomic effect on pioglitazone PK/PD is reported. |
| PGx | Wu_2025 | not_relevant | 0 | 0 | The paper investigates the effect of pioglitazone on kidney stone risk and lipid metabolism, not how genetic variants alter the pharmacokinetic or pharmacodynamic parameters of the drug itself. |
| PGx | Yang_2020 | not_relevant | 0 | 0 | The paper uses pioglitazone as an example of a drug identified by a network-based discovery strategy for aging, but does not report any pharmacogenomic effects on its PK or PD parameters. |
| PGx | Yates_2012 | not_relevant | 0 | 0 | The paper describes statistical methods for analyzing time-dependent inhibition of CYP3A4 and does not report any pharmacogenomic effects (gene variants) on pioglitazone PK/PD. |
| PGx | van_2013 | not_relevant | 0 | 0 | The study investigates drug-drug interactions (pioglitazone inhibiting rosuvastatin transport) and does not report how a gene variant affects the PK/PD of pioglitazone. |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-10-05 02:46 UTC</sub>
